You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

72 Results
Guidelines and Advice
Status: Current
ID: 26-1
Version: 2
Mar 2017
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Adjuvant, Curative
Jan 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Jan 2024
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Updated
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Nov 2023
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Adjuvant, Palliative
Sep 2022
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Neoadjuvant
Jan 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    melphalan - oral tablets
ODB - General Benefit
    prednisone
Jun 2019
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Jun 2024

Pages